Alto Neuroscience Inc. (NYSE: ANRO) has initiated a Phase 2b randomized, placebo-controlled trial of ALTO-207 for treatment-resistant depression, the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA